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ABSTRACT 
Purpose: Corneal endothelial dysfunction is a major indicator for corneal graft 
surgery worldwide, and whilst surgical intervention via a range of posterior lamellar 
surgeries has proven to be hugely beneficial, challenges remain. This is especially 
so where the anterior chamber is relatively shallow, as is often the case in the Asian 
population, though not exclusively so. Here, we introduce a new insertion device to 
deliver endothelial graft tissue for Descemet stripping automated endothelial 
keratoplasty (DSAEK).  
Methods: A new surgical tool was designed and manufactured so as to enable a 
one-step insertion of corneal graft tissue into the anterior chamber based on a 
pressure-flow concept, rather than the a pull-through one. This was tested ex vivo to 
assess endothelial cell damage, then performed in 12 first-in-man surgeries. 
Results: Pre-cut DSAEK lenticules implanted in donor corneas ex vivo via the new 
technique showed less endothelial cell damage occurs compared to a pull-through 
technique. Grafts were successful in all patients receiving the new surgery, with no 
cases of primary graft failure.   
Conclusion: The newly developed DSAEK inserter is a simple and useful tool for 
endothelial graft delivery, lessening intraoperative mechanical stress on the graft 
tissue
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INTRODUCTION 1 
Although Descemet’s membrane endothelial keratoplasty (DMEK)1 has been 2 
supplanting Descemet stripping automated keratoplasty (DSAEK) in recent years, 3 
leading to faster visual rehabilitation and better visual outcome, graft detachments, 4 
failures and difficulties manipulating the delicate tissue are associated risks, which 5 
may in part account for the situation that established DSAEK surgery is often 6 
preferred to DMEK. In DSAEK, however, folding and grasping the donor tissue with 7 
forceps or pull-through technique using glides to enable graft insertion through a 8 
small incision can represent a challenge,2-4 and this is particularly so in Asian eyes, 9 
which tend to have shallower anterior chambers. One significant complication with 10 
DSAEK is endothelial cell loss, especially in the early postoperative period.5-7 11 
Consequently, there is a growing demand for a surgical graft delivery system for 12 
DSAEK that allows for easy manipulation of graft tissue, whilst also minimizing 13 
mechanical stress on the graft and helping prevent anterior chamber collapse during 14 
surgery. Partially in response to this need, techniques such as the Sheets glide 15 
insertion method and the Tan Endoglide were specifically developed for Asian eyes, 16 
and their utility has been reported.8,9 17 
 In cataract surgery, the shift away from intraocular lens (IOL) insertion using 18 
forceps to graft insertion using injectors has undoubtedly contributed to improved 19 
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outcomes. In DSAEK, the superiority of graft insertion devices over forceps has not 20 
been demonstrated unequivocally,10-12 nevertheless, the use of insertion devices has 21 
become increasingly popular in recent years. Essentially, DSAEK insertion devices 22 
can be categorized into three groups based on their mechanism of action; the folding 23 
technique (i.e. taco-folding), pull-through designs (glides) and push-in designs 24 
(injectors).13 By applying the fundamental concept of an IOL injector to the DSAEK 25 
insertion device, we have developed a new surgical tool in which the donor graft is 26 
introduced into anterior chamber along with a steady flow of balanced salt solution 27 
(BSS). Here, we describe the device’s design, mode of action, and use in 12 first-in-28 
man surgeries. 29 
 30 
METHODS 31 
Device Design and Surgical Technique 32 
The new DSAEK graft inserter consists of the main body of the device, which is 33 
made of polypropylene, with a hydrophilically coated and flexible polyethylene 34 
platform at its front end on which the pre-cut graft lenticule is placed just prior to 35 
surgery, endothelial cells facing upwards. A movable polypropylene cartridge is fitted 36 
to the main body, along with a valved conduit made of silicone rubber. A 2.5ml 37 
syringe, to be filled with BSS prior to surgery, is continuous with the main body of the 38 
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inserter. Overall, the device measures 8.5 mm in width, is 63 mm long, and weighs 39 
1.85 g. The major and minor axes of the lumen of the new inserter’s nozzle are 3.57 40 
mm and 2.02 mm, respectively. It is intended for single use (Figure 1). 41 
 To operate, the syringe is first filled with BSS after which the plunger is 42 
partially depressed to lubricate the surface of the hydrophilic platform with BSS. The 43 
DSAEK graft is then carefully placed onto the platform (Figure 2A), endothelial cells 44 
facing upwards, using forceps. Importantly, the surface of the graft insertion platform 45 
remains lubricated owing to the hydrophilic nature of the platform’s coating, which is 46 
a key design feature to prevent the graft from adhering to the platform. After the graft 47 
coated with viscoelastic gel is in place on the platform, the flexible platform and graft 48 
are partially rolled up and drawn within the main body of the inserter by steadily 49 
moving the cartridge forward (Figure 2B).This is achieved via another important 50 
design feature, i.e. a valved conduit located on the inner tube of the movable 51 
cartridge. Thus, when the cartridge is moved forward over the platform holding the 52 
graft, a negative pressure is generated which keeps the graft in position as the 53 
flexible platform is partially rolled up and enclosed in the inner cylinder of main body 54 
of the device. This closed system for fluid flow has an additional benefit in that it 55 
prevents anterior chamber collapse when delivering the corneal graft into the 56 
recipient's eye. Prior to inserting the graft into the recipient’s eye the insertion device 57 
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is rotated 180 degrees around its axis, so that the corneal endothelial cells on the 58 
inner aspect of the partially rolled-up lenticel face away from the posterior corneal 59 
surface once injected into the anterior chamber. During graft insertion through a pre-60 
made, 4.6 mm incision in the peripheral cornea, the leading edge of the cartridge tip 61 
of the inserter enters the anterior chamber, but is not projected deeply into the 62 
chamber. The graft can then be delivered into anterior chamber, along with BSS, by 63 
gently depressing the syringe’s plunger (Figure 2C). The graft moves readily into the 64 
anterior chamber because water molecules retained on the hydrophilic polymers of 65 
the platform on which it sits work as carrier to allow the graft to slip smoothly across 66 
and off the platform once the flow of BSS is started. 67 
 68 
Ex Vivo Testing 69 
A single donor cornea, obtained from the SightLife Eye Bank (Seattle, WA, USA) was 70 
used as an ex vivo proxy to represent the recipient tissue. This was secured on an 71 
artificial anterior chamber (K20-2125 Barron Artificial Anterior Chamber, Katena, 72 
Denville, NJ, USA). A 20 gauge chamber maintainer (#19092, Moria) was used to 73 
maintain the tissue’s shape, after which a 5.0 mm corneal incision was created in the 74 
corneal periphery to allow graft insertion. Ten research pre-cut corneal lenticules 75 
from the same Eye Bank were obtained, and DSAEK was carried out in 10 test 76 
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surgeries; five using the new DSAEK insertion system and five using a 5.0 mm Busin 77 
spatula (#19098, Moria, Doylestown, PA) and the pull-through technique. The mean 78 
thickness of pre-cut donor grafts used for the pull-through Busin glide surgery was 79 
113 ± 11 µm (average ± SD, range; 96-124 µm); for the inserter test-surgeries it was 80 
126 ± 22 m (range; 98-149 m).  Donor lenticules were 8 mm in diameter. After 81 
each procedure the graft tissue was removed from the anterior chamber and stained 82 
with 0.25% alizarin Red S and 4 % trypan blue for 90 s to assess the general level of 83 
endothelial cell damage14 using Image J in accordance with method of Saad and 84 
associates.15 85 
 86 
Clinical Applicability 87 
Twelve patients underwent DSAEK with the new insertion device between July 2016 88 
and Jan 2017, after which intra- and early postoperative outcomes were examined. 89 
Underlying diseases were cytomegalovirus endotheliitis (3 eyes), pseudophakic 90 
bullous keratopathy (2 eyes), post intraocular surgery (2 eyes), exfoliation syndrome 91 
(2 eyes), Fuchs’ endothelial corneal dystrophy (2 eyes), and argon laser iridotomy-92 
induced bullous keratopathy (1 eye) and the average observation period was 172 93 
days ± 62 days (range, 89-265 days). In particular, we sought signs of a failure of the 94 
graft tissue to be smoothly and successfully inserted into the eye, of anterior 95 
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chamber collapse during surgery, and of graft dislocation or detachment afterwards. 96 
The work adhered to the tenets of the Declaration of Helsinki and was approved by 97 
the institutional review board of Osaka University Hospital. 98 
 All surgeries were performed by one of two surgeons (T.S., K.N.), both of 99 
whom had previously used a Busin glide to conduct DSAEK, either under local 100 
retrobulbar anestasia and facial nerve block or under general anaesthesia. Pre-cut 101 
donor corneas (target thickness, 100 m) from SightLife Eye Bank were used in all 102 
cases. After the anterior chamber maintainer was set-up, Descemet membrane and 103 
the endothelium were stripped from the recipient’s central cornea (this step was 104 
omitted in the case of non-Descemet stripping automated endothelial keratoplasty 105 
(nDSAEK)).16 An inferior peripheral iridectomy was then created with 25-gauge 106 
vitreous cutter, and two nasal and temporal vent incisions were fashioned at the 107 
inner side of the recipient corneal marking. Following its trephination, the donor graft 108 
was placed on the flexible, hydrophilic graft insertion platform of the new inserter. 109 
After applying dispersive ophthalmic viscoelastic material (Viscoat; Alcon 110 
laboratories, Fort Worth, TX) over the entire endothelial graft, the platform and graft 111 
were rolled up and enclosed into the main body of the device by sliding the movable 112 
cartridge forward. (Figure 2 and Supplementary Information 1). As mentioned earlier, 113 
as a result of the negative pressure exerted by the inserter, the lenticule is rolled up 114 
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and engulfed into the main body of the device (while still on the flexible hydrophilic 115 
platform) without being touched with forceps or any other surgical tool. Also, we note 116 
here that after the placement of the graft on the platform (the last time it is contacted 117 
physically) it should be coated with a dispersive ophthalmic viscosurgical formulation 118 
rather than a cohesive form to lessen the risk of clumps of material being flushed into 119 
the anterior chamber when BSS flow is initiated. Once the graft had been loaded into 120 
the inserter, the nozzle was placed into anterior chamber through the 4.6 mm 121 
temporal corneoscleral tunnel and the graft delivered into the anterior chamber along 122 
with a flow of BSS by simply depressing the plunger of the syringe. The anterior 123 
chamber maintainer was turned off during graft insertion (Figure 2 and 124 
Supplementary Information 1), its use only being needed during the peripheral 125 
iridectomy using vitreous cutters and Descemetorhexis. After removal of the insertion 126 
device an air tamponade was performed to ensure good graft-host apposition. All 127 
patients held their posture facing upward on their beds for three hours following the 128 
operation. 129 
 130 
RESULTS 131 
Preliminary ex vivo test surgeries established the successful working of the 132 
procedure and the new insertion device. Figure 3 shows the post-operative corneal 133 
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staining patterns for all 10 test surgeries, five conducted using the Busin glide and 134 
five with the new inserter. No unusual staining characteristics of note were detected 135 
in the corneas following surgery with the new inserter. Average endothelial cell loss, 136 
calculated as pixels in the endothelial damage area divided by pixels in the whole 137 
area x 100%, was 10.8 ± 2.7 % in the new inserter group and 23.9 ± 2.0 % in the 138 
Busin glide group, pointing to the clinical promise of the new DSAEK inserter. 139 
All twelve surgeries in patients using the new DSAEK inserter were 140 
successful and uneventful. Donor grafts were smoothly inserted into anterior 141 
chamber in all cases, and in no cases did an anterior chamber collapse occur. All 142 
grafts became successfully attached with no incidences of graft dislocation or 143 
detachment, postoperatively. No primary graft failures occurred in the immediate 144 
postoperative period. 145 
 146 
DISCUSSION 147 
Although endothelial cell loss after DSAEK is reported to be influenced by both donor 148 
and recipient factors,17 it is widely accepted that donor tissue manipulation during 149 
surgery can directly contribute to cell loss and damage. Currently, the pull-through 150 
technique is a standard procedure for DSAEK and one of the most widely used 151 
devices is the Busin Glide. In this approach, a rolled-up donor graft is delivered into 152 
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anterior chamber and spontaneously opens, causing less endothelial cell damage 153 
compared to the taco-folding method.18-20 However, pull-through techniques are 154 
accompanied by the risk of anterior chamber collapse during graft insertion, and this 155 
can occur too often in the eyes of Asian patients, in which the angle tends to be 156 
narrow and the anterior chamber depth shallow. In the new surgery, described here, 157 
a combination of the negative pressure, which allows the graft lenticule to become 158 
incorporated within the new surgical device without the need for mechanical 159 
manipulation, aligned to the hydrophilic nature of the flexible platform’s surface, 160 
ensuring that the graft moves smoothly off the platform in the absence of any need to 161 
pull-through, means that mechanical contact with the graft tissue during the 162 
procedure introduced here is minimised, thus reducing the likelihood of graft trauma. 163 
 Commercially available surgical insertion tools for DSAEK, which are based 164 
on push-in designs include the Neusidl corneal injector (Fischer Surgical, Arnold, 165 
MO, USA) and the Endoserter (Ocular Systems, Winston‑Salem, NC, USA).14 Both 166 
are single use devices, and several studies have reported the clinical outcomes of 167 
their use.10,11,21 These devices have a platform which holds the donor graft tissue, as 168 
does ours. However, neither of the aforementioned designs incorporates a negative 169 
pressure system to help hold the graft on the platform, so there is a risk that the graft 170 
can become inadvertently dislodged from its proper position on the platform during 171 
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surgical manipulation. DSAEK with all injector devices requires the platform to be 172 
introduced into the anterior chamber to deliver the graft, however, the negative 173 
pressure feature of our new inserter means that, unlike with the Neusidl and 174 
Endoserter devices, we do not need to perform continuous anterior chamber 175 
irrigation. This is a significant advantage because continuous irrigation increases the 176 
intraoperative pressure within the anterior chamber, which can lead to the unwanted 177 
situation whereby the graft accidentally flows out of the anterior chamber through the 178 
incision as the insertion device is being removed. The new DSAEK device described 179 
here utilizes the flow of BSS for graft injection into the anterior chamber. Only a small 180 
volume of BSS (approximately 0.1 ml) is required, and this carries along with the 181 
unfolding graft lenticule to achieve graft insertion in a quick and simple one-step 182 
action.  183 
 A clinical trial of this approach in a larger number of the patients has been 184 
initiated to extend the results presented here. The aim is to enhance the application 185 
of DSAEK to eyes, especially those at risk of endothelial cell damage because of a 186 
shallow anterior chamber. In summary, initial first-in-man studies indicate that the 187 
new graft inserter can provide for endothelial graft delivery for DSAEK without 188 
anterior chamber collapse and can results in successful graft attachment.189 
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FIGURE LEGENDS 
FIGURE 1.   
Photographic and schematic images of the new DSAEK insertion device. (A) Without 
and (B) with the syringe attached. (C) A valved conduit made of silicone rubber 
located on the inner tube of the movable cartridge. 
 
FIGURE 2.  
(A) DSAEK graft is placed onto the platform. (B) By sliding the movable cartridge 
forward the flexible platform and graft are rolled-up and drawn into the inserter via 
the effect of negative pressure. (C) The graft can be easily delivered into the anterior 
chamber, carried along by the flow of BSS flow simply by depressing the syringe 
plunger.  
 
FIGURE 3. 
Corneal staining patterns after use of (A) the new inserter and (B) a Busin glide in 10 
ex vivo test DSAEK surgeries. No unusual staining patterns are seen after a test-
surgery with the new inserter, and the area of endothelial cell damage compares 
favorably to that which resulted from Busin glide surgery. 
 
